Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03AZR
|
|||
| Former ID |
DIB006826
|
|||
| Drug Name |
Berubicin
|
|||
| Synonyms |
Berubicin hydrochloride; RTA-744; RTA-769; WP-744; WP-769; Anthracycline derivative topoisomerase II inhibitor (cancer), MD Anderson; Anthracycline derivative topoisomerase II inhibitor (cancer), Reata; Berubicin (intravenous), Reata Pharmaceuticals; Berubicin (oral, cancer); Anthracycline topoisomerase II inhibitor (oral, cancer), MD Anderson Cancer Center; Anthracycline topoisomerase II inhibitor (oral, cancer), Reata Pharmaceuticals; Berubicin (oral, cancer), Reata Pharmaceuticals
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1] | |
| Company |
MD Anderson Cancer Center
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C34H35NO11
|
|||
| Canonical SMILES |
CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)OCC6=CC=CC=C6
|
|||
| InChI |
1S/C34H35NO11/c1-16-33(44-15-17-7-4-3-5-8-17)20(35)11-24(45-16)46-22-13-34(42,23(37)14-36)12-19-26(22)32(41)28-27(30(19)39)29(38)18-9-6-10-21(43-2)25(18)31(28)40/h3-10,16,20,22,24,33,36,39,41-42H,11-15,35H2,1-2H3/t16-,20-,22-,24-,33+,34-/m0/s1
|
|||
| InChIKey |
FIGNGSHKNAHTSH-JJMFXPFOSA-N
|
|||
| CAS Number |
CAS 677017-23-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA topoisomerase II (TOP2) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00538343) RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases. U.S. National Institutes of Health. | |||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.